english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view.
24 July 2020

Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease

 NEWS UPDATE  The detailed results of four comparative trials of hydroxychloroquine in patients with covid-19 were released in late July 2020: two trials in patients hospitalised for covid-19, and two others in patients who were not hospitalised and had milder forms of the disease.
24 July 2020

"Top Texts of 2020", from the editors of Prescrire International

1 August 2020

Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain

 NEWS UPDATE  The antiviral drug remdesivir was authorised in the European Union in early July 2020 for the treatment of certain adults and adolescents with severe covid-19 requiring supplemental oxygen. It was only granted conditional authorisation, because the data submitted were incomplete on many fronts. The drug company needs to resolve many uncertainties surrounding remdesivir's adverse effects and efficacy.
13 July 2020

Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial

 NEWS UPDATE  Some detailed preliminary results were released on 23 June 2020 from a randomised trial in patients hospitalised for covid-19 (the “Recovery” trial). Adding the corticosteroid dexamethasone (for up to 10 days) to usual care reduced 28-day mortality in patients receiving oxygen or mechanical ventilation, but appeared unnecessarily dangerous in other patients.
24 June 2020

Andexanet alfa (Ondexxya°) as an antidote to xabans: inadequate clinical evaluation

FEATURED REVIEW The evaluation of andexanet alfa for the management of severe bleeding in patients receiving apixaban or rivaroxaban is inadequate. When bleeding occurs in a patient receiving a xaban, the key action is to put in place proven emergency supportive measures.
Full review (4 pages) available for download by subscribers.
1 July 2020

In the July-August issue of Prescrire International: aflibercept (Eylea°) in diabetic macular oedema without visual impairment

FREE DOWNLOAD What is the efficacy of aflibercept in patients with diabetic macular oedema without visual impairment at the time of diagnosis?
Full text available for free download.
1 July 2020

Proper evaluation, for patients' sake

EDITORIALProper drug evaluation, based on trials designed to provide sufficiently high-level evidence and conclusive results, using patient-relevant clinical outcomes, is the best way of ensuring that drugs are used judiciously, without causing unnecessary harm.
1 July 2020

Pulmonary arterial hypertension: sometimes drug-induced

Many drugs can cause pulmonary arterial hypertension, which sometimes improves when treatment is halted.
1 July 2020

Prescrire's annual drug packaging review: slow progress and dangers

The drug packaging market is improving, but there are also still many examples as of 2020 that pose a danger to patients, in particular children and pregnant women. These flaws affect prescribers, pharmacists and nurses through the complications they cause.
1 July 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90